Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positive interim results from the ongoing Phase I study of its lead development programme, ALX-0081, an anti-thrombotic treatment. ALX-0081 is a novel ´first-in-class´ therapeutic Nanobody® targeting von Willebrand Factor (vWF)...A large step forward in the fight against African sleeping sickness
... They have coupled the human protein ApoL-1 with a nanobody in order to very specifically eliminate the infect...t is needed: onto the surface of the parasite. nanobody carries ApoL-1 variant to the parasite Under the ...selier, VIB researchers have previously produced a nanobody (a very small antibody) that targets and binds to ...PipelineReview.com - Biotech News & Online Store - ABLYNX REACHES ...
... ABLYNX REACHES MILESTONE IN TNF-alpha NANOBODY(R) COLLABORATION AS WYETH ... Nanobody® is a registered trademark of Ablynx NV. ...ABLYNX PROVIDES AN R&D UPDATE ANNOUNCING IT HAS SUCCESSFULLY GENERATED ...
ABLYNX PROVIDES AN R&D UPDATE ANNOUNCING IT HAS SUCCESSFULLY GENERATED NANOBODIES(R) AGAINST GPCRs AND PRESENTS NEW ... Nanobody® constructs have been ...